ePrints@IIScePrints@IISc Home | About | Browse | Latest Additions | Advanced Search | Contact | Help

Pre-clinical toxicity & immunobiological evaluation of DNA rabies vaccine & combination rabies vaccine in rhesus monkeys (Macaca mulatta)

Kumar, Dinesh B and Kumar, Uday P and Krishna, Prasanna T and Kalyanasundaram, S and Suresh, P and Jagadeesan, V and Hariharan, S and Naidu, Nadamuni A and Krishnaswamy, Kamala and Rangarajan, PN and Srinivasan, VA and Reddy, GS and Sesikeran, B (2013) Pre-clinical toxicity & immunobiological evaluation of DNA rabies vaccine & combination rabies vaccine in rhesus monkeys (Macaca mulatta). In: INDIAN JOURNAL OF MEDICAL RESEARCH, 137 . pp. 1072-1088.

[img]
Preview
PDF
ind_jou_med_res_137_1072_2013.pdf - Published Version

Download (586kB) | Preview
Official URL: http://icmr.nic.in/ijmr/2013/june/content.htm

Abstract

Background & objectives: Pre-clinical toxicology evaluation of biotechnology products is a challenge to the toxicologist. The present investigation is an attempt to evaluate the safety profile of the first indigenously developed recombinant DNA anti-rabies vaccine DRV (100 mu g)] and combination rabies vaccine CRV (100 mu g DRV and 1.25 IU of cell culture-derived inactivated rabies virus vaccine)], which are intended for clinical use by intramuscular route in Rhesus monkeys. Methods: As per the regulatory requirements, the study was designed for acute (single dose - 14 days), sub-chronic (repeat dose - 28 days) and chronic (intended clinical dose - 120 days) toxicity tests using three dose levels, viz. therapeutic, average (2x therapeutic dose) and highest dose (10 x therapeutic dose) exposure in monkeys. The selection of the model i.e. monkey was based on affinity and rapid higher antibody response during the efficacy studies. An attempt was made to evaluate all parameters which included physical, physiological, clinical, haematological and histopathological profiles of all target organs, as well as Tiers I, II, III immunotoxicity parameters. Results: In acute toxicity there was no mortality in spite of exposing the monkeys to 10XDRV. In sub chronic and chronic toxicity studies there were no abnormalities in physical, physiological, neurological, clinical parameters, after administration of test compound in intended and 10 times of clinical dosage schedule of DRV and CRV under the experimental conditions. Clinical chemistry, haematology, organ weights and histopathology studies were essentially unremarkable except the presence of residual DNA in femtogram level at site of injection in animal which received 10X DRV in chronic toxicity study. No Observational Adverse Effects Level (NOAEL) of DRV is 1000 ug/dose (10 times of therapeutic dose) if administered on 0, 4, 7, 14, 28th day. Interpretation & conclusions: The information generated by this study not only draws attention to the need for national and international regulatory agencies in formulating guidelines for pre-clinical safety evaluation of biotech products but also facilitates the development of biopharmaceuticals as safe potential therapeutic agents.

Item Type: Journal Article
Additional Information: Copyright for this article belongs to the INDIAN COUNCIL MEDICAL RES, PO BOX 4911 ANSARI NAGAR, NEW DELHI 110029, INDIA
Keywords: Biotech products; combination rabies vaccine (CRV); DNA rabies vaccine (DRV); pre-clinical toxicology; PVRV; purified vero cell-derived inactivated rabies virus vaccine; safety evaluation; toxicology
Department/Centre: Division of Biological Sciences > Molecular Reproduction, Development & Genetics
Depositing User: Id for Latest eprints
Date Deposited: 14 Mar 2014 10:13
Last Modified: 14 Mar 2014 10:15
URI: http://eprints.iisc.ac.in/id/eprint/48574

Actions (login required)

View Item View Item